Hepion Pharmaceuticals, Inc. (CTRVP)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Revenues | - | - | - | |
| Research and development | 423,277 | 2,762,709 | 7,136,679 | |
| General and administrative | 919,488 | 1,695,550 | 1,367,169 | |
| Asset impairment loss | 402,746 | - | - | |
| Total operating expenses | 1,745,511 | 4,458,259 | 8,503,848 | |
| Loss from operations | -1,745,511 | -4,458,259 | -8,503,848 | |
| Interest income (expense) | 4,866 | -474,570 | 49,536 | |
| Inducement expense | - | - | - | |
| Change in fair value of contingent consideration and derivative financial instruments | 698,073 | 66,881 | 4,529,100 | |
| Loss before income taxes | -1,042,572 | -4,865,948 | -3,925,212 | |
| Income tax benefit | - | - | - | |
| Net loss | -1,042,572 | -4,865,948 | -3,925,212 | |
| Net loss per common share basic | -0.09 | -0.72 | -0.68 | |
| Net loss per common share diluted | -0.09 | -0.72 | -0.68 | |
| Weighted-average common shares outstanding basic | 11,328,122 | 6,718,962 | 5,799,126 | |
| Weighted-average common shares outstanding diluted | 11,328,122 | 6,718,962 | 5,799,126 | |